Search

Search Results

• BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

  Lorenzo Falchi, Jessica M Baron, Carrie Anne Orlikowski, Alessandra Ferrajoli

  e2016011

  2016-02-10

  https://doi.org/10.4084/mjhid.2016.011

  4421

  PDF: 1528

  HTML: 3725

• GREEK CONSENSUS ON CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATMENT

  Sotirios Sachanas, Theodoros Vassilakopoulos, Maria Angelopoulou, sotirios Papageorgiou, Emmanouil Spanoudakis, Maria Bouzani, Maria Dimou, Panagiotis Panagiotidis

  e2025014

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.014

  1523

  HTML: 184

  PDF: 905

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 2- FOCUS ON THERAPY

  Michele Bibas, Shayna Sarosiek , Jorge Castillo

  e2025015

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.015

  2720

  PDF: 2101

  HTML: 374

• WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE

  Maddalena Mazzucchelli, Anna Maria Frustaci, Marina Deodato, Roberto Cairoli, Alessandra Tedeschi

  e2018004

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.004

  7819

  PDF: 2481

  HTML: 2115

  Table 1.: 246

  Table 2.: 257

  Table 3.: 237

  Table 4.: 232

• RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY?

  Antonio Cuneo, Robin Foà

  e2019024

  2019-02-27

  https://doi.org/10.4084/mjhid.2019.024

  2791

  PDF: 1700

  HTML: 392

• BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.

  Stefano Molica

  e2025053

  2025-06-29

  https://doi.org/10.4084/MJHID.2025.053

  1790

  PDF: 1017

  HTML: 345

• Pathogenetic mechanism of macular edema during a treatment with ibrutinib: a case presentation.

  Cristina Mauro, Livio Pupo, Lucia Cardillo, Fabiana Esposito, Elisa Buzzatti, Marco Lombardo, Massimo Cesareo, Adriano Venditti, Massimiliano Postorino, Maria Ilaria Del Principi

  e2026009

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.009

  639

  PDF: 505

  Html: 315

• Response to ibrutinib of a refractory IgA lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation

  Francesca Maria Quaglia, Gian Matteo Rigolin, Elena Saccenti, Massimo Negrini, Eleonora Volta, Melissa Dabusti, Maria Ciccone, Antonio Urso, Michele Laudisi, Antonio Cuneo

  e2019057

  2019-08-29

  https://doi.org/10.4084/mjhid.2019.057

  1646

  PDF: 996

  HTML: 295

• INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ERA OF TARGET DRUGS

  Livio Pagano, Davide Facchinelli, Dr.

  e2018063

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.063

  2134

  PDF: 1149

  HTML: 344

• CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL

  Ugo Testa, Dr. Elvira Pelosi, Dr. Germana Castelli, Dr. Alberto Fresa, Prof. Luca Laurenti

  e2024045

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.045

  3863

  PDF: 1686

  HTML: 88

• A case of Pseudo-Richter Transformation following zanubrutinib discontinuation in CLL

  Luca Laurenti, Tommaso Quaranta, Annamaria Tomasso, Luca Stirparo, Pier Luigi Abbate, Arianna Bakacs, Natalia Cappoli, Arianna Di Napoli, Dimitar Efremov, Flaminia Bellisario, Valter Gattei, Carmelo Caldarella, Maria Luisa Calcagni, Francesco Autore, Idanna Innocenti

  e2026070

  2026-09-01

  https://doi.org/10.4084/MJHID.2026.070

  53

  PDF: 32

  Html: 5

• BING-NEEL SYNDROME: ILLUSTRATIVE CASES AND COMPREHENSIVE REVIEW OF THE LITERATURE

  Marzia Varettoni, Irene Defrancesco, Luca Diamanti, Enrico Marchioni, Lisa Maria Farina, Anna Pichiecchio

  e2017061

  2017-10-18

  https://doi.org/10.4084/mjhid.2017.061

  3580

  PDF: 1552

  HTML: 1354

• Ibrutinib associated cardiovascular events in a patient wearing an implanted loop recorder

  Daniel Rivera, Koichi Takahashi, Jean-Benard Durand, Alessandra Ferrajoli

  e2021044

  2021-06-28

  https://doi.org/10.4084/MJHID.2021.044

  1061

  PDF: 408

  HTML: 150

• NOVEL DRUGS IN FOLLICULAR LYMPHOMA

  Giuseppe Rossi, Antonella Anastasia

  e2016061

  2016-11-01

  https://doi.org/10.4084/mjhid.2016.061

  5728

  PDF: 1565

  HTML: 1661

  Untitled: 257

• Orbital Infiltration in a Patient with Waldenström Macroglobulinemia: Need for Multidisciplinary Approach and Comparison with the Literature

  Riccardo Paggi, Francesca Mariotti, Jessica Mencarini, Silvia Bresci, Irene Capolmi, Filippo Bartalesi, Beatrice Borchi, Luca Nassi, Alessandro Maria Vannucchi, Alessandro Bartoloni

  e2023028

  2023-04-28

  https://doi.org/10.4084/MJHID.2023.028

  1094

  PDF: 823

  HTML: 427

• Zanubrutinib as upfront treatment in de-novo B-cell prolymphocytic leukemia: the case of two elderlies.

  Silvia Giorgi, Giovanna Leonardi, Monica Maccaferri, Elena Sbadili, Carlo Caterina, Giovanni Fera, Ambra Paolini, Leonardo Potenza, Anna Candoni, Mario Luppi, Roberto Marasca

  e2025061

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.061

  1373

  PDF: 611

  Html: 269

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  2275

  PDF: 1834

  HTML: 836

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 1: EPIDEMIOLOGY, PATHOGENESIS, CLINICOPATHOLOGIC CHARACTERISTICS, DIFFERENTIAL DIAGNOSIS, RISK STRATIFICATION, AND CLINICAL PROBLEMS

  Michele Bibas, Shayna Sarosiek, Jorge J. Castillo

  e2024061

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.061

  3072

  PDF: 3338

  HTML: 728

• “IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”

  Sara Martinelli, Antonio Cuneo, Gian Matteo Rigolin

  e2016047

  2016-10-15

  https://doi.org/10.4084/mjhid.2016.047

  4057

  PDF: 1097

  HTML: 3896

  Untitled: 187

  Cneo. Fig.1: 125

  Untitled: 120

  Untitled: 145

  Untitled: 154

• AUTOLOGOUS STEM CELL TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA STILL A VALID TREATMENT OPTION, OR IS THE GAME OVER ?

  Fabienne McClanahan, Peter Dreger

  e2012071

  2012-11-06

  https://doi.org/10.4084/mjhid.2012.071

  2557

  PDF: 847

  HTML: 1772

• PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations

  Michele Bibas

  e2024007

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.007

  3707

  PDF: 2593

  HTML: 1615

• INFECTIONS AND FOLLICULAR LYMPHOMA: IS THERE A LINK?

  Francesco Zallio, Giulia Limberti, Marco Ladetto

  e2017035

  2017-05-01

  https://doi.org/10.4084/mjhid.2017.035

  3339

  PDF: 1064

  HTML: 2380

• UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)

  José Luis Piñana, Estela Giménez, Lourdes Vázquez, María Ángeles Marcos, Manuel Guerreiro, Rafael Duarte, Ariadna Pérez, Carlos de Miguel, Ildefonso Espigado, Marta González-Vicent, María Suarez-Lledó, Irene García-Cadenas, Rodrigo Martino, Angel Cedillo, Monserrat Rovira, Rafael de la Cámara, David Navarro, Carlos Solano

  e2024065

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.065

  4303

  Suppl. Files: 1212

  PDF: 1130

  Html: 260

• OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT Outcome of DLBCL patients relapsing after ASCT

  Ulrike Bacher, Stefanie von Matt, Yara Banz, Behrouz Mansouri, Urban Novak, Thomas Pabst

  e2023025

  2023-04-28

  https://doi.org/10.4084/MJHID.2023.025

  1457

  HTML: 396

  PDF: 995

  Suppl. Files: 487

• Monoclonal gammopathy of neurological significance: a case report and a novel approach

  Mario Biglietto, Martina Gherardini, Raffaele Maglione, Azzurra Anna Romeo, Luciano Fiori, Piera Giovangrossi, Alessandro Pulsoni, Ugo Coppetelli

  e2025034

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.034

  960

  PDF: 846

  HTML: 198

• CLINICAL CHARACTERISTICS AND PROGNOSTIC FACTORS IN PRIMARY BREAST DIFFUSE LARGE B-CELL LYMPHOMA

  guangliang Chen, Dou-dou Li, Sufen Sufen, Shiyu Jiang, Qunling Zhang, jia jin, Zuguang Xia, Yizhen Liu, Xiaojian Liu, Yanzhe Zhu, Yu Chen, Lingli Gu, Xiaonan Hong, Junning Cao, Rong Tao, Fangfang Lv

  e2022066

  2022-08-27

  https://doi.org/10.4084/MJHID.2022.066

  1175

  PDF: 686

  HTML: 265

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  2433

  PDF: 1776

  HTML: 989

• West Nile Virus Encephalitis in A Patient with Chronic Lymphocytic Leukemia

  Giovanni D'Arena, Carmela Palladino, Michele Bosco, Michele Gambardella

  e2025010

  2024-12-31

  https://doi.org/10.4084/MJHID.2025.010

  1441

  PDF: 1128

  HTML: 172

• CIRCCTNNA1 IS UPREGULATED IN MANTLE CELL LYMPHOMA AND PREDICTS POOR SURVIVAL BY SPONGING MIR-34A TO INCREASE CELL PROLIFERATION.

  Xuebing Jing, Cong Lu, Chao Song, Qingkun Han

  e2022047

  2022-06-29

  https://doi.org/10.4084/MJHID.2022.047

  716

  PDF: 554

  HTML: 276

• EVOLVİNG PARADİGMS İN THE MANAGEMENT OF PRİMARY IMMUNE THROMBOCYTOPENİA İN ADULTS: FROM CORTİCOSTEROİDS TO TARGETED BİOLOGİC THERAPİES

  Massimo Martino, Laura Giordano, Maria Bruna Greve, Violetta Marafioti, Caterina Alati

  e2026067

  2026-09-01

  https://doi.org/10.4084/MJHID.2026.067

  50

  PDF: 51

  Html: 2

• CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES

  Ugo Testa, Prof. Patrizia Chiusolo, Dr. Elvira Pelosi, Dr. Germana Castelli, Giuseppe Leone

  e2024031

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.031

  2290

  PDF: 2111

  HTML: 216

• NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL

  Dimitar Efremov, Adrian Wiestner, Luca Laurenti

  e2012067

  2012-10-09

  https://doi.org/10.4084/mjhid.2012.067

  2615

  PDF: 878

  HTML: 9056

  Efremov 1: 254

  Efremov 2: 216

• Guidance for Facing Dilemmas of Hematopoietic Stem Cell Transplant Clinicians in the Coronavirus Disease 2019 (COVID-19) Pandemic: An Iranian Consensus

  Seied Asadollah Mousavi, Soroush Rad, Tahereh Rostami, Mohammad Vaezi, Hosein Kamranzadeh, Davood Babakhani, Sahar Tavakoli, Maryam Barkhordar, Tanaz Bahri, Amirabbas Hedayatiasl, azade kiumarsi

  e2020050

  2020-06-28

  https://doi.org/10.4084/mjhid.2020.050

  1365

  PDF: 716

  HTML: 228

• MANAGING INVASIVE FUNGAL INFECTIONS DURING ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION: A 2025 UPDATE

  Martina Quattrone, Alessia Di Pilla, Sara Brunetti, Antonio Giordano, Luana Fianchi, Livio Pagano, Marianna Criscuolo

  e2025064

  2025-08-31

  https://doi.org/10.4084/MJHID.2025.064

  2548

  PDF: 1008

  HTML: 290

• THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.

  Francesco Maura, Lucia Farina, Paolo Corradini

  e2016045

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.045

  4155

  PDF: 1197

  HTML: 2106

  Fig.1: 228

  Fig. 2: 123

  Table 1: 224

  Table2: 243

  Table 3: 223